KRAS Gene Mutation Testing
CIGNA Government Services will allow KRAS Gene Mutation Testing in the care of patients with metastatic colon cancer who are being considered for an Epidermal Growth Factor Receptor inhibitor as second line therapy effective October 1, 2008.
Generally these are billed by the reference lab performing the test for Medicare beneficiaries. The allowed CPT codes are 83890, 83892(2), 83898, 83904(2), 83907, 83909(2), and 83912. No other use of this test is approved for Medicare payment at this time.